for Veterans and the Public
Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations
This revision (March 8, 2017) incorporates updates to treatment regimens for chronic hepatitis C virus (HCV) infection, genotype 1 and 3. New and updated sections include:
- Updated "Summary Table: Treatment Considerations and Choice of Regimen for HCV-Monoinfected and HIV/HCV-Coinfected Patients"
- A new section titled "Genotype 3-Infected Patients Who Have Failed NS5A-Based Therapy"
- Revisions to "Interpretation of Resistance-Associated Substitutions"
- Information on HCV resistance genotyping and sample reports (Appendices B and C)
- HBV testing and monitoring recommendations prior to starting HCV DAA (Appendix D)
The previous update included the following:
- A new table on "Genotype 1-Infected Patients Who Have Failed Treatment with DAA-Based Therapy"
- Updated drug-drug interactions with HCV direct antiviral agents, including HIV antiretroviral agents (see Table 25 and Table 26)
The Panel continues to recommend that HIV/HCV-coinfected patients receive the same HCV antiviral regimens as HCV-monoinfected patients unless ledipasvir/sofosbuvir is being considered, in which case a 12-week regimen should be used.
Also see reference tables on the Classification of DAAs for treatment regimens by class.